Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia

Abstract

A gain-of-function mutation in the fibroblast growth factor receptor 3 gene (FGFR3) results in achondroplasia (ACH), the most frequent form of dwarfism. Constitutive activation of FGFR3 impairs bone formation and elongation and many signal transduction pathways. Identification of new and relevant compounds targeting the FGFR3 signaling pathway is of broad importance for the treatment of ACH, and natural plant compounds are prime drug candidate sources. Here, we found that the phenolic compound (-)-epicatechin, isolated from Theobroma cacao, effectively inhibited FGFR3’s downstream signaling pathways. Transcriptomic analysis in an Fgfr3 mouse model showed that ciliary mRNA expression was modified and influenced significantly by the Indian hedgehog and PKA pathways. (-)-Epicatechin is able to rescue mRNA expression impairments that control both the structural organization of the primary cilium and ciliogenesis-related genes. In femurs isolated from a mouse model (Fgfr3 ^Y367C/+) of ACH, we showed that (-)-epicatechin eliminated bone growth impairment during 6 days of ex vivo culture. In vivo, we confirmed that daily subcutaneous injections of (-)-epicatechin to Fgfr3 ^Y367C/+ mice increased bone elongation and rescued the primary cilium defects observed in chondrocytes. This modification to the primary cilia promoted the typical columnar arrangement of flat proliferative chondrocytes and thus enhanced bone elongation. The results of the present proof-of-principle study support (-)-epicatechin as a potential drug for the treatment of ACH.

References

[1] Rousseau F et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 1994, 371: 252-254

[2] Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev. Dyn., 2017, 246: 291-309

[3] Minina E, Kreschel C, Naski MC, Ornitz DM, Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev. Cell, 2002, 3: 439-449

[4] Haycraft CJ et al. Intraflagellar transport is essential for endochondral bone formation. Development, 2007, 134: 307-316

[5] Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ. FGF Signaling during embryo development regulates cilia length in diverse epithelia. Nature, 2009, 458: 651-654

[6] Zhan D, Xiang W, Guo F, Ma Y. Basic fibroblast growth factor increases IFT88 expression in chondrocytes. Mol. Med Rep., 2017, 16: 6590-6599

[7] Kunova Bosakova M et al. Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies. Hum. Mol. Genet, 2018, 27: 1093-1105

[8] Kunova Bosakova M et al. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase. Proc. Natl. Acad. Sci. USA, 2019, 116: 4316-4325

[9] Martin L et al. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia. Hum. Mol. Genet, 2018, 27: 1-13

[10] Morales TI. Chondrocyte moves: clever strategies? Osteoarthr. Cartil., 2007, 15: 861-871

[11] Zhang W et al. Expanding the genetic architecture and phenotypic spectrum in the skeletal ciliopathies. Hum. Mutat., 2018, 39: 152-166

[12] Haycraft CJ, Serra R. Cilia involvement in patterning and maintenance of the skeleton. Curr. Top. Dev. Biol., 2008, 85: 303-332

[13] Ascenzi M-G et al. Effect of localization, length and orientation of chondrocytic primary cilium on murine growth plate organization. J. Theor. Biol., 2011, 285: 147-155

[14] Legeai-Mallet L, Savarirayan R. Novel therapeutic approaches for the treatment of achondroplasia. Bone, 2020, 141: 115579

[15] Lorget F et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet., 2012, 91: 1108-1114

[16] Savarirayan R et al. C-Type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med., 2019, 381: 25-35

[17] Savarirayan R et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet, 2020, 396: 684-692

[18] Cádiz-Gurrea M et al. Bioactive compounds from theobroma cacao: effect of isolation and safety evaluation. Plant Foods Hum. Nutr., 2019, 74: 40-46

[19] Cady RJ, Durham PL. Cocoa-enriched diets enhance expression of phosphatases and decrease expression of inflammatory molecules in trigeminal ganglion neurons. Brain Res., 2010, 1323: 18-32

[20] Jang YJ et al. Theobromine inhibits differentiation of 3T3-L1 cells during the early stage of adipogenesis via AMPK and MAPK signaling pathways. Food Funct., 2015, 6: 2365-2374

[21] Cordero-Herrera I, Martín MA, Goya L, Ramos S. Cocoa flavonoids protect hepatic cells against high-glucose-induced oxidative stress: relevance of MAPKs. Mol. Nutr. Food Res., 2015, 59: 597-609

[22] Jonquoy A et al. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. Hum. Mol. Genet, 2012, 21: 841-851

[23] Pannier S et al. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. Biochim. Biophys. Acta, 2009, 1792: 140-147

[24] Arnaiz O, Cohen J, Tassin A-M, Koll F. Remodeling Cildb, a popular database for cilia and links for ciliopathies. Cilia, 2014, 3

[25] Boyden ED et al. Recurrent dominant mutations affecting two adjacent residues in the motor domain of the monomeric kinesin KIF22 result in skeletal dysplasia and joint laxity. Am. J. Hum. Genet., 2011, 89: 767-772

[26] Kobayashi T, Tsang WY, Li J, Lane W, Dynlacht BD. Centriolar kinesin Kif24 interacts with CP110 to remodel microtubules and regulate ciliogenesis. Cell, 2011, 145: 914-925

[27] Mikami A et al. Molecular structure of cytoplasmic dynein 2 and its distribution in neuronal and ciliated cells. J. Cell. Sci., 2002, 115: 4801-4808

[28] Abramyan J. Hedgehog signaling and embryonic craniofacial disorders. J. Dev. Biol., 2019, 7: 9

[29] Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N. Engl. J. Med, 2011, 364: 1533-1543

[30] Mick DU et al. Proteomics of primary cilia by proximity labeling. Dev. Cell, 2015, 35: 497-512

[31] Murakami S et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev., 2004, 18: 290-305

[32] Prein C, Beier F. ECM signaling in cartilage development and endochondral ossification. Curr. Top. Dev. Biol., 2019, 133: 25-47

[33] Thouverey C, Caverzasio J. Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep., 2015, 4: 711

[34] Komla-Ebri D et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J. Clin. Investig., 2016, 126: 1871

[35] Shung C-Y, Ota S, Zhou Z-Q, Keene DR, Hurlin PJ. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II. Hum. Mol. Genet., 2012, 21: 4628-4644

[36] Gutiérrez-Salmeán G et al. Effects of (-)-epicatechin on a diet-induced rat model of cardiometabolic risk factors. Eur. J. Pharmacol., 2014, 728: 24-30

[37] Xing J et al. Epicatechin alleviates inflammation in lipopolysaccharide-induced acute lung injury in mice by inhibiting the p38 MAPK signaling pathway. Int. Immunopharmacol., 2019, 66: 146-153

[38] De Los Santos S, Palma-Flores C, Zentella-Dehesa A, Canto P, Coral-Vázquez RM. (-)-Epicatechin inhibits development of dilated cardiomyopathy in δ sarcoglycan null mouse. Nutr. Metab. Cardiovasc. Dis., 2018, 28: 1188-1195

[39] Dower JI et al. Does epicatechin contribute to the acute vascular function effects of dark chocolate? A randomized, crossover study. Mol. Nutr. Food Res., 2016, 60: 2379-2386

[40] Raucci A, Laplantine E, Mansukhani A, Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem., 2004, 279: 1747-1756

[41] Min B-J et al. Whole-exome sequencing identifies mutations of KIF22 in spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type. Am. J. Hum. Genet., 2011, 89: 760-766

[42] Taylor SP et al. Mutations in DYNC2LI1 disrupt cilia function and cause short rib polydactyly syndrome. Nat. Commun., 2015, 6

[43] Chen L, Li C, Qiao W, Xu X, Deng C. A Ser(365)->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum. Mol. Genet, 2001, 10: 457-465

[44] Bruce SJ et al. Inactivation of Patched1 in the mouse limb has novel inhibitory effects on the chondrogenic program. J. Biol. Chem., 2010, 285: 27967-27981

[45] Milenkovic L, Goodrich LV, Higgins KM, Scott MP. Mouse patched1 controls body size determination and limb patterning. Development, 1999, 126: 4431-4440

[46] Stone DM et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature, 1996, 384: 129-134

[47] Chen Y, Struhl G. Dual roles for patched in sequestering and transducing Hedgehog. Cell, 1996, 87: 553-563

[48] Altaba ARI. Catching a Gli-mpse of Hedgehog. Cell, 1997, 90: 193-196

[49] Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development, 1999, 126: 3915-3924

[50] Iwata T et al. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum. Mol. Genet, 2000, 9: 1603-1613

[51] Antal MC et al. Adenylate cyclase type III is not a ubiquitous marker for all primary cilia during development. PLoS One, 2017, 12: e0170756